Abstract
Behavioral studies in animals are an important part of neuropharmacological research, because they integrate findings from in vitro pharmacology, chemical neuroanatomy and electrophysiology at the systems level, thereby bridging the gap between basic research on one hand, and the development of pharmacological treatment with clinical trials on the other hand. Animal behavioral models of neuropsychiatric diseases (such as fear/anxiety disorders, depression, addiction, or schizophrenia) are, therefore, an eminent part of preclinical neuropharmacology. We review here recent neuropharmacological findings on prepulse inhibition (PPI) and fear-potentiation of the startle response (FPS) as behavioral models for sensorimotor gating deficits in neuropsychiatric disorders and fear/anxiety-related disorders, respectively.
Keywords: anxiety, fear, fear-potentiated startle, prepulse inhibition, schizophrenia
Current Neuropharmacology
Title: Startle Response Modulation as a Behavioral Tool in Neuropharmacology
Volume: 1 Issue: 2
Author(s): M. Koch and M. Fendt
Affiliation:
Keywords: anxiety, fear, fear-potentiated startle, prepulse inhibition, schizophrenia
Abstract: Behavioral studies in animals are an important part of neuropharmacological research, because they integrate findings from in vitro pharmacology, chemical neuroanatomy and electrophysiology at the systems level, thereby bridging the gap between basic research on one hand, and the development of pharmacological treatment with clinical trials on the other hand. Animal behavioral models of neuropsychiatric diseases (such as fear/anxiety disorders, depression, addiction, or schizophrenia) are, therefore, an eminent part of preclinical neuropharmacology. We review here recent neuropharmacological findings on prepulse inhibition (PPI) and fear-potentiation of the startle response (FPS) as behavioral models for sensorimotor gating deficits in neuropsychiatric disorders and fear/anxiety-related disorders, respectively.
Export Options
About this article
Cite this article as:
Koch M. and Fendt M., Startle Response Modulation as a Behavioral Tool in Neuropharmacology, Current Neuropharmacology 2003; 1 (2) . https://dx.doi.org/10.2174/1570159033477161
DOI https://dx.doi.org/10.2174/1570159033477161 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Herbal Highs: Review on Psychoactive Effects and Neuropharmacology
Current Neuropharmacology Genetic Susceptibility to Behavioural and Psychological Symptoms in Alzheimer Disease
Current Alzheimer Research Transcranial Magnetic Stimulation on Rodent Models
CNS & Neurological Disorders - Drug Targets Poly (Lactic-co-Glycolic Acid) & Tocopheryl Polyethylene Glycol Succinate Nanoparticles for the Treatment of Different Brain Cancers
Anti-Cancer Agents in Medicinal Chemistry Peptides as Signaling Inhibitors for Mammalian MAP Kinase Cascades
Current Pharmaceutical Design Neurobehavioral and Cognitive Changes Induced by Hypoxia in Healthy Volunteers
CNS & Neurological Disorders - Drug Targets Animal Models for Investigating Benign Essential Blepharospasm
Current Neuropharmacology Schizophrenia and the Neglect Syndrome: Parietal Contributions to Cognitive Dysfunction in Schizophrenia
Current Psychiatry Reviews New Insights into the Pathogenesis of Fibromyalgia Syndrome: Important Role of Peripheral and Central Pain Mechanisms
Current Rheumatology Reviews Patterns of Cognitive Impairment in Neurological Disease
Current Psychiatry Reviews Neurosarcoidosis
Current Neuropharmacology Cell and Gene-Based Therapies for the Lysosomal Storage Diseases
Current Gene Therapy Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis
Current Pharmaceutical Design N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Current Psychiatry Reviews WNT4 Signaling in Female Gonadal Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Progress of Imaging Agents for Parkinson’s Disease
Current Neuropharmacology Cannabis Use and Psychosis: Theme Introduction
Current Pharmaceutical Design Microfluidic Devices for Automation of Assays on Drosophila Melanogaster for Applications in Drug Discovery and Biological Studies
Current Pharmaceutical Biotechnology Cognitive Dysfunction in Depression: Lessons Learned from Animal Models
CNS & Neurological Disorders - Drug Targets Molecular Aspects of Melatonin Treatment in Tinnitus: A Review
Current Drug Targets